LexaGene is a molecular diagnostics company developing a fully automated, rapid pathogen detection system for use at the point-of-need where samples are collected, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection.
LexaGene’s MiQLab™ system aims to transform pathogen detection in multi-billion-dollar markets, namely human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access markets that need critical answers in less time.
To provide fully automated, rapid molecular testing at the point-of-need for accurate detection and characterization of pathogens to improve the health and safety of people and their pets.
Transforming the way diseases are detected, fueling research, and improving pandemic prevention through broad adoption of open-access technology.
LexaGene’s patented microfluidic system was invented by company CEO and Founder, Dr. Jack Regan, who was a lead scientist in developing a predecessor instrument designed for bio-warfare surveillance and adopted by the Department of Homeland Security for the BioWatch Program, and a second R&D instrument that was designed for detecting respiratory pathogens from nasal swab samples. The development of these instruments was supported by $20M in government funding.
LexaGene was founded in October of 2016 to bring open-access diagnostics to markets in need of better testing.
Lexa/ Defender of
Gene/ What we detect